Bard PowerPort Lawsuit: Defective Port-a-Cath Claims
PRACTICE AREAS
A Bard PowerPort lawsuit alleges the implanted port catheter fractures, migrates, or harbors bacteria because barium sulfate degrades the ChronoFlex catheter body. As of the August 2026 JPML report, 3,734 defective Port-a-Cath cases are pending in MDL 3081 before Judge David G. Campbell. If you suffered injuries, needed your medical device surgically removed, or had to undergo revision surgery, our national law firm can help file a Bard PowerPort lawsuit to seek compensation.
Filing Bard PowerPort claims nationwide from our Houston office. Free consultation: You don't pay unless we win.
Call 713-622-7271Bard PowerPort Lawsuit Update 2026
The Bard PowerPort multidistrict litigation docket is growing rather than resolving. Federal lawsuits are consolidated in MDL 3081, In re: Bard Implanted Port Catheter Products Liability Litigation, before Judge David G. Campbell in the District of Arizona. The United States Judicial Panel on Multidistrict Litigation (MDL) statistics report listed 3,734 pending lawsuits, a gain of 170 in one month.
Two bellwether cases have now reached a jury. The first produced a partial verdict. The second bellwether case, the first fracture case to go to trial, opened in Phoenix on August 18, 2026, and remains in the bellwether process as of publication.
No global settlement exists, and no Bard PowerPort lawsuit has been resolved through a court-approved settlement program. However, the outcomes of the Bard PowerPort litigation may influence future designs and regulations for similar medical devices.
Bard PowerPort Bellwether Trial Timeline
MDL 3081 is centralized before Judge David G. Campbell in the District of Arizona. This timeline tracks the court's scheduling orders and the dates set for each bellwether plaintiff. Select one or more names below to load their dates.
01Select a plaintiff
02Docket timeline
If you had a Bard PowerPort implanted and later developed an infection, a blood clot, or a catheter fracture, the bellwether schedule affects how quickly your claim needs to be filed. We review these cases at no cost, and there is no fee unless we win.
Dates reflect case management orders and scheduling entries in In re: Bard Implanted Port Catheter Products Liability Litigation, MDL No. 3081, United States District Court for the District of Arizona. Court schedules change, and a date listed here may be continued or vacated by later order.
This timeline is general information only. It is not legal advice, it is not a case evaluation, and using it does not create an attorney-client relationship. Filing deadlines are strict and vary by state. If you would rather write than call, use our contact page.
Bard PowerPort MDL 3081
Here is the Bard PowerPort MDL 3081 at a glance:
Bard PowerPort litigation status: MDL 3081
In re: Bard Implanted Port Catheter Products Liability Litigation, U.S. District Court for the District of Arizona, before Judge David G. Campbell.
How MDL 3081 Reached Its Initial Trials
The Judicial Panel on Multidistrict Litigation (JPML) consolidated the cases into MDL 3081. The District Judge overseeing it is Judge Campbell. Defendants include C.R. Bard, Bard Access Systems, and parent Becton, Dickinson and Company. The initial stages moved quickly through preliminary case management.
Judge Campbell ordered the parties to cooperate on several issues during pretrial proceedings, and the fact discovery phase ran through January 2025. Plaintiff fact discovery, product identification, and disclosure were enforced throughout 2025.
The theory of legal action draws on federal adverse event reports. The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database collects medical device reports from mandatory reporters, as well as voluntary reports from healthcare providers and patients. The FDA’s 510(k) clearance process has been criticized for allowing insufficient long-term testing. Additionally, the Bard port lawsuits allege the parent company used the FDA’s Alternative Summary Reporting program to keep the catheter failure reports out of the MAUDE database until 2019.
- The FDA’s MAUDE database reported 438 PowerPort complications from December 2025 to February 2026.
- The FDA received reports of 122 blood clots related to PowerPorts from late 2025 to early 2026.
The federal court selected a bellwether pool from the discovery group. Six bellwether trials were selected, plus one alternative bellwether case. Of the first six bellwether trials, three PowerPort bellwether trial plaintiffs alleged infection, two alleged blood clots, and one alleged port catheter fracture.
Case Management Order No. 38 confirmed a bellwether trial schedule running early March through December 2026.
Pretrial motions defined the shape of the first trial. Defendants elected not to file common-issue summary judgment motions, instead filing case-specific motions and expert testimony in October 2025. In March 2026, the judge overseeing the case denied nearly all of Bard’s summary judgment motions. Judge Campbell also restricted Bard’s expert testimony from Kimberly Trautman and an FDA expert.
The First Bellwether Trial: Cook v. Bard
Robert Cook, a Minnesota cancer patient, was hospitalized and had his colorectal cancer treatment delayed after a serious infection from a Bard Port catheter device. Prospective jurors were screened, and the first PowerPort bellwether trial, an infection case, opened April 21, 2026.
Expert testimony in Robert Cook’s case testified that the hospital abandoned Bard ports in 2014.
Jurors sided with Bard and Becton, Dickinson and Company on failure to adequately warn, failure to instruct, and consumer fraud, deadlocked on design defect, and reportedly indicated they believed the defective Bard PowerPort device could have been made safer.
So, Bard won the unlawful trade practices count. Jurors deliberated roughly 11 hours before returning a partial defense verdict and repeatedly asked for clarification on design defect, failure to warn, and superseding cause. No unanimous verdict was reached on what drives most of the pending MDL docket.
The first trial plaintiff moved forward for a new trial.
Why the Schedule Shifted: The Miller Case
When Judge Campbell selected the PowerPort bellwether trial slate, it included Wanda Miller, Robert Cook, Judy Hicks, Kimberly Divelbliss, May Lattanzio, and Lloyd Sorensen, with a bellwether case filed by Peter James designated as the alternate. Wanda Miller was slated to be the second bellwether and go to trial in July. She died in February, and her family chose not to continue Miller’s case. Divelbliss replaced the Miller case in the upcoming bellwether trial.
Instead of promoting the alternate, Judge Campbell decided to hold only five PowerPort bellwether trials. Wanda Miller’s death reshaped the track for blood clot injuries alleged in Bard PowerPort lawsuits, as she was one of the two lawsuits alleging injuries related to thrombosis.
Now, Judy Hicks carries the deep vein thrombosis theory alone. Her DVT case goes to trial in December. If the next PowerPort bellwether trial for blood clots produces another split or partial defense verdict, the Bard PowerPort MDL process will continue into 2027 without a unanimous verdict on blood clot injuries caused by the defective product, which is a substantial share of plaintiffs.
Second Bellwether In Progress: Divelbliss v. Bard
Kimberly Divelbliss, of New Mexico, got the implantable port PowerPort in July 2017. Less than two years later, when she underwent emergency port removal surgery, surgeons found the polyurethane catheter had broken. Part of the fractured catheter was lodged in her heart.
Design defect is the legal issue the next PowerPort bellwether trial puts before jurors. It is the first bellwether trial for a fractured PowerPort catheter. The upcoming bellwether trial opened in Phoenix on August 18, 2026, and is in progress as of publication.
Unlike Cook, the upcoming fracture trial claims Bard packed the attached catheter tubing with excess polyurethane and barium sulfate particles. Researchers found that the loss of barium sulfate particles creates a fractured catheter surface. The engineering theory relies heavily on this peer-reviewed study.
The defense asked to divide the defective device proceedings into two phases, with the jury first deciding liability and then considering punitive damages separately. The plaintiff’s attorneys opposed, arguing that most of the punitive damages evidence goes directly to the parent company’s knowledge of the alleged defects.
Bard PowerPort Bellwether Trial Schedule (MDL 3081, D. Ariz., Judge David G. Campbell)
Bellwether trials are test cases. In the bellwether process, neither side is bound by the outcome, but the way juries react can shape how both sides value the remaining cases. This is why the upcoming fracture trial and deep vein thrombosis tracks are being monitored closely. The following is the Bard PowerPort bellwether trial schedule.
Bellwether Trial Dates | Bellwether Case | Bard PowerPort Injury Type |
|---|---|---|
April 21 to May 8, 2026 | Cook v. C.R. Bard (23-cv-01975) | Infection, polyurethane catheter |
August 18 to September 4, 2026 | Divelbliss v. C.R. Bard (23-cv-01627) | Catheter fracture and migration, silicone Groshong, subclavian placement |
October 13 to October 30, 2026 | Lattanzio v. C.R. Bard (24-cv-00680) | Infection linked to silicone failure |
December 1 to December 18, 2026 | Hicks v. C.R. Bard (23-cv-01703) | Thrombosis and blood clots |
February 2 to February 19, 2027 | Sorensen v. C.R. Bard (23-cv-02557) | Infection, polyurethane catheter |
What Comes After the Bard PowerPort Fracture Trial
The third trial is Lattanzio, another Bard port catheter infection case. The hearing on prospective juror questionnaires is scheduled for September. Hick’s thrombosis case follows in December, and Sorensen closes the bellwether trials in February 2027.
Future trials depend on what the Divelbliss jury decides. A plaintiff verdict would give the defective product claim the outcome the Cook jury failed to deliver. A defense verdict would strengthen Bard’s position that the initial trials validate the device.
Case management conferences continue monthly, with the next conference expected to address post-trial motion practice, the Lattanzio pretrial schedule, and docket growth.
If the bellwether trials do not produce a global Bard PowerPort settlement, remaining cases may be remanded to their original courts. That would only occur after the parties agree that the bellwether trials have run their course or the federal court determines that coordinated pretrial proceedings are complete. The manufacturer continued to market the PowerPort throughout the federal multidistrict litigation, and the docket has continued to grow with each status conference and trial to date.
Defective Bard PowerPort Litigation Status & The Judicial Panel on Multidistrict Litigation's Findings
Case volume in MDL 3081 is tracked in the Judicial Panel on Multidistrict Litigation’s monthly pending MDL reports and is updated regularly. Pretrial proceedings, bellwether trials, deadlines for the discovery process, and plaintiff fact sheet obligations are set by case management orders issued in MDL 3081, which the court updates as early trial dates shift.
Our attorneys review Bard PowerPort lawsuit cases through our defective medical device and pharmaceutical injury practice. This posture will look familiar to anyone following the firm’s work in active federal MDL proceedings such as the Ozempic litigation: consolidated discovery, bellwether testing, and no potential settlement figures until the upcoming trial data is in.
Why Bard PowerPort Devices Fail: The Barium Sulfate & ChronoFlex Defect
Lawsuits allege that the Bard PowerPort failures occur because barium sulfate particles blended into the ChronoFlex polyurethane tubing separate from the polymer once that attached catheter sits in blood. Essentially, the excessive barium sulfate in the tubing weakens PowerPort catheters. The mechanical failures allow for bacterial colonization. This is why the alleged defect drives both the catheter device fracture claims and the port catheter infection claims in MDL 3081.
The implantable port catheter is also known as port-a-cath, chemotherapy port, or implantable venous access device. It’s a small injection port with a raised center and a polyurethane catheter implanted under the skin of the chest, connected to a tube threaded into a large central vein near the heart. Bard PowerPort devices are used for chemotherapy, long-term IV antibiotics, dialysis, blood products, and contrast-enhanced CT imaging, which is why the port-a-cath remains implanted for extended periods.
Bard Access Systems, a subsidiary of Becton Dickinson and Company, markets the device under the names PowerPort, PowerPort ClearVUE, PowerPort ISP, SlimPort, X-Port, and Groshong.
Bard PowerPort lawsuits allege design flaws caused serious injuries. Theories surround product liability, not medical malpractice or placement issues.
The same alleged degradation explains the catheter fracture cases, the port infection cases, and the thrombosis cases, which is why the MDL 3081 bellwether pool draws from all three.
Product liability lawyers describe this as a design defect claim: the allegation is that the ChronoFlex formulation itself was unreasonably dangerous as designed, and that safer alternative catheter materials were available and in use by competitors. Paired with it is a failure-to-warn claim, alleging that Bard knew from its own internal testing and complaint files that the tubing degraded in vivo and failed to inform implanting physicians or patients.
Patients who want to see what has been reported to regulators can review adverse event reports filed with the FDA for implanted port catheters. Claims built on this mechanism are product liability claims built on design defect and failure to warn.
Has the Bard PowerPort Been Recalled?
No, the FDA hasn’t issued any recalls of the Bard PowerPort device due to barium sulfate catheter degradation, and the Bard PowerPort remains on the market and in active clinical use. A recall is not a prerequisite for a product liability claim. MDL 3081 is proceeding on design defect and failure-to-warn theories with no recall behind it, and patients with a currently implanted port should not have it removed on the strength of a lawsuit.
FDA recalls are regulatory actions. Product liability claims are civil actions for injuries caused by device failure, and thousands of pending Bard PowerPort lawsuits exist without one.
Bard PowerPort Complications and Injuries: Fracture, Migration, Infection, & Blood Clots
Bard PowerPort complications fall into three injury tracks, and MDL 3081 is testing each one on its own bellwether schedule. Catheter fracture and fragment migration, bloodstream infection and sepsis, and thrombosis with pulmonary embolism are the three. Knowing which track a Bard PowerPort lawsuit falls into tells a claimant which trial result will move their case.
Each track carries a different evidentiary profile. Fracture claims usually come with physical proof: a retrieved fragment, a retrieval procedure report, imaging showing tubing separated from the port body. Thrombosis claims are supported by duplex ultrasound or CT angiography. Infection claims depend more heavily on differential causation, because a cancer patient on chemotherapy is immunocompromised and a defendant will argue the bloodstream infection came from somewhere other than the port catheter. That distinction is not academic, and the first bellwether verdict demonstrated it.
Bard PowerPort Catheter Fracture & Fragment Migration
Catheter fracture is the failure mode at issue in the Bard PowerPort trial now underway in Phoenix. When degraded ChronoFlex tubing separates, the free fragment does not remain in place. Venous blood flow carries it toward the heart, and fragments have been recovered from the right atrium, the right ventricle, and the pulmonary arteries. This is a catheter embolism, and it is a medical emergency even when the patient feels nothing.
Retrieval is typically an endovascular procedure performed by interventional radiology or interventional cardiology using a snare passed through the femoral or jugular vein, and it is not always successful on the first attempt. When percutaneous retrieval fails, the alternative is open surgery. Patients report chest pain, palpitations, arrhythmia, and shortness of breath, though some Bard PowerPort fractures are clinically silent and turn up incidentally on a chest X-ray or CT ordered for something else entirely. Fragment migration also causes vessel perforation, myocardial injury, and, in the worst cases, cardiac arrest.
Symptoms that should prompt imaging include a port that no longer flushes or draws blood, swelling or burning at the port site during infusion, a palpable change under the skin, and new chest pain or palpitations in a patient with an implanted port.
Bard PowerPort Infection, Bacteremia, & Sepsis
Pitting on the catheter surface provides bacteria with a foothold that antibiotics struggle to clear, and once biofilm forms on an implanted port, the standard answer is to remove the device. That means explant surgery, a temporary PICC line for continued access, a course of IV antibiotics, and a waiting period before a new port can be placed. Common organisms in these catheter-related bloodstream infections include Staphylococcus species, and the clinical course ranges from local port-site infection to bacteremia, sepsis, and septic shock.
The patient population is what makes Bard PowerPort infection claims serious. Implanted ports go overwhelmingly into cancer patients, so an infection is not a hospital stay that resolves and ends. It is an interruption of chemotherapy, and the treatment delay can have consequences that extend well beyond the infection itself. Reich & Binstock handles chemotherapy-related injury claims, such as the Taxotere litigation, where the same overlap between treatment and injury appears. Federal infection-control guidance is set out in the CDC’s guidance on central line-associated bloodstream infections.
Bard PowerPort Blood Clots: DVT, Pulmonary Embolism, & Vascular Injury
A roughened catheter surface promotes thrombus formation along the tubing and inside the vein that houses it. Clinically, that presents as catheter-related deep vein thrombosis in the upper extremity, subclavian or jugular vein thrombosis, superior vena cava syndrome, or a pulmonary embolism when a clot breaks loose and travels to the lungs. Symptoms include arm, neck, or facial swelling on the side of the implant, visible collateral veins across the chest, and sudden shortness of breath or pleuritic chest pain.
Stiffened or migrating tubing can also erode into a vessel wall or the heart wall, causing vascular perforation, hemothorax, pericardial effusion, or cardiac tamponade, which is a surgical emergency. Long-term consequences include post-thrombotic syndrome and permanent anticoagulation. The thrombosis track is the fourth Bard PowerPort bellwether trial, Hicks v. C.R. Bard, set for December 1 through December 18, 2026. Infusion complications can also arise from how a line is used rather than from the device itself, including IV infiltration injuries caused during infusion.
Our firm also handles malpractice-related IV infiltration throughout Texas.
Who Qualifies for the Bard Port Catheter Lawsuit?
Three conditions determine whether a Bard PowerPort lawsuit is viable: a Bard-manufactured implanted port, a documented complication tied to that port catheter, and medical intervention as a result. If a port was placed and something went wrong, requiring a surgeon or interventional radiologist to address it, the Bard PowerPort claim is worth reviewing.
- Received a Bard-manufactured implanted port, including PowerPort, PowerPort ClearVUE, PowerPort ISP, PowerPort Duo, SlimPort, X-Port, or a Groshong or ChronoFlex catheter configuration
- Experienced catheter fracture, fragment migration, catheter embolism, device movement or flipping, bloodstream infection or sepsis, deep vein thrombosis, pulmonary embolism, or vessel or organ perforation
- Required surgical removal, port revision, explant, or emergency endovascular retrieval
- Have medical records identifying the device, including the implant operative report, product sticker or catalog number, and post-implant imaging
- The serious injury, death, or other serious complication occurring within the statute of limitations in your state
Hospitals log the manufacturer, catalog number, and lot number of every implanted device in the operative record. Our law firm can gather evidence, such as records, as long as you know the brand of your port-a-cath and the approximate year it was implanted.
The evaluation pattern here follows the firm’s history of IVC filter injury litigation, another implanted-device case built on medical-device fracture and migration. To find out if you qualify to file a Bard PowerPort lawsuit, start a free case review with our port catheter attorneys or call 713-622-7271. Bard PowerPort claims are handled on contingency, so there is no fee unless we win.
Bard Port Catheter Lawsuit Settlement Amounts
No global settlement has been reached as of August 2026. All figures are purely speculation at this point, and settlement offers will depend on the specific details of each case and how the jury reacts to key issues in the bellwether trials.
Bard PowerPort settlement amounts may range from $10,000 to $1 million. Bard PowerPort catheter infection-only cases may settle between $30,000 and $100,000. The attached catheter fracture cases could have settlements from $175,000 to $350,000.
However, as all parties prepare, it’s important to understand that this is a projection with limited data. Per-plaintiff estimates for these specific manufacturing issues are based on unrelated medical device failure settlements. These are completely unrelated adverse event reports.
Factors that drive the Bard PowerPort settlement, whenever settlement negotiations begin, are already evident in how the bellwether group was selected and how the first trial went. The deadlock in the design defect claim involving Robert Cook shows both parties that, even in severe infections, Bard PowerPort catheter infection-only cases are difficult to prove were caused by a defective product and may not resolve cleanly.
Deep vein thrombosis and device fracture claims, where an imaged blood clot or mechanical failure is proven, don’t carry the same risk. Plaintiffs asking what their Bard PowerPort lawsuit is worth should understand that the risk is tied to what their medical records support.
The following factors help determine potential Bard PowerPort settlement value:
Potential Settlement Value Factor | Why It Matters | Documentation That Supports It |
|---|---|---|
Bard PowerPort complication type | Fractured catheter and thrombosis claims present clearer causation than infection-only claims | Imaging showing catheter failure or fragment location, venous duplex or CT angiography, retrieval procedure report |
Surgical intervention | Revision, explant, and emergency retrieval raise value | Operative reports |
Duration & cost of treatment | Long-term treatments & repeat procedures increase financial losses | Billing, hospital & facility records, follow-up visit notes |
Interruption of cancer treatment | Delay in chemotherapy treatment is a harm distinct from the medical device failure itself | Oncology notes documenting the pause, revised chemotherapy treatment schedule, restaging CT scans |
Permanent injury or wrongful death | Determines whether the claim is a survival action, a wrongful death action, or both | Death certificate, autopsy report, disability rating, permanent impairment findings |
Lost income & earning capacity | Converts time out of work into financial losses | Pay records, tax returns, employer statements, vocational assessment |
Quality of device identification records | Weak identification threatens the claim regardless of injury severity | Implant operative report, product sticker, catalog & lot number |
Claimants can review verdicts and settlements the firm has recovered in mass tort and device litigation for context on past results. The closest structural comparison is defective implant claims involving revision surgery, where the second surgery drives both the compensatory damages and evidence.
How to File a Bard Port Lawsuit
A Bard PowerPort lawsuit is an individual claim, not a class action. Injured patients’ cases are filed into multidistrict litigation (MDL) 3081 or transferred there by the Judicial Panel on Multidistrict Litigation for coordinated pretrial proceedings, but each individual plaintiff keeps their own PowerPort case, their own individual settlement, and right to trial. Plaintiffs aren’t bound by another person’s outcome, and plaintiffs don’t have to opt out of anything to preserve a personal injury case.
Filing a Bard PowerPort lawsuit starts with confirming the device. Everything downstream, including the plaintiff fact sheet and the census registry obligations MDL 3081 imposes, depends on establishing that the port implanted was a Bard product. Here is the step-by-step legal process:
- Free case review confirming device, injury, and timeline
- Medical record retrieval, including the implant operative report and device identification
- Device verification against the Bard product catalog and lot numbers
- Complaint filed directly into MDL 3081 or transferred by the JPML
- Plaintiff fact sheet completed and served on defense counsel
- Coordinated pretrial discovery, with the individual case preserved for remand or trial
The following evidence is needed to file a lawsuit for Bard PowerPort injuries:
- Implant operative report and hospital records
- Device product sticker, catalog number, or lot number
- Imaging showing catheter fracture, migration, or fragment location
- Removal, explant, or revision surgery records
- Infection cultures, blood cultures, ER admissions, and hospitalization records
- Oncology records documenting any interruption in chemotherapy
- Proof of lost wages and out-of-pocket costs
Claimants do not gather most of this themselves. Record retrieval is the firm’s job, and a patient who arrives with nothing more than a hospital name and an approximate implant year has provided enough to get started.
Damages in an Implantable Port Catheter Lawsuit
Patients can pursue compensation in a Bard PowerPort lawsuit that falls into three groups:
- Economic damages: medical treatment, lost wages, and other financial losses
- Non-economic damages: emotional distress and the human cost of the preventable injuries
- Punitive damages: the jury may award punitive damages in a Bard PowerPort catheter lawsuit, depending on how the discovery process continues. If internal company documents or other evidence shows that Bard Access Systems, Inc. was grossly negligent, the jury may choose to award punitive damages to plaintiffs.
- Derivative claims: involving families when a patient suffers permanent and significant injuries or doesn’t survive the fracture, infection, or other complication. This isn’t incidental to the Bard PowerPort multidistrict litigation because a major part of the pending MDL dockets involve cancer patients whose medical complications interrupted the cancer treatment they didn’t have time to lose.
The following are recoverable damages in a Bard PowerPort lawsuit settlement:
- Past and future medical expenses, including revision, explant, and endovascular retrieval surgery
- Lost wages and diminished earning capacity
- Pain and suffering, and physical impairment
- Mental anguish and loss of enjoyment of life
- Disfigurement and scarring from port removal procedures
- Wrongful death damages
When a patient dies, the Bard PowerPort lawsuit splits in two. Survival actions cover damages patients incur before death, including medical bills and conscious pain and suffering, and they pass to the estate. A wrongful death claim filed by a surviving spouse, child, or parent is separate and compensates the family’s own loss. Patients who survive with permanent damage from lacerated blood vessels, a retained catheter fragment, a heart attack, stroke, or other serious complication may have catastrophic injury claims involving permanent impairment.
Deadlines to File a Port Catheter Claim
The deadline for filing a Bard PowerPort lawsuit depends on the plaintiff’s home state. Multidistrict litigation (MDL) 3081 is a venue for the coordinated discovery phase, but the Bard PowerPort MDL doesn’t create or extend deadlines for the legal process. Texas residents have two years for most injury claims, and other states’ filing deadlines range from one to six years.
However, the discovery rule is important in Bard port catheter lawsuits. Fractured catheter migration claims result from serious injuries that are silent for years. Most patients learn about injuries suffered from their implantable port PowerPort catheter from chest X-rays or CT scans ordered for other reasons.
Claims for PowerPort failures will be based on the date of discovery, not on when the patient had the Bard PowerPort implanted. However, some states have a statute of repose that can bar product liability lawsuits regardless of when a patient’s injury was discovered. If you suffered injuries from a Bard PowerPort implant, contact our law firm to determine if you’re eligible to file a lawsuit.
Bard PowerPort Filing Deadline Checker
In most states, your deadline to file a Bard PowerPort claim runs from the date your complication was diagnosed rather than the date the port was implanted. Answer the questions below for an estimated window. Treat the result as a starting point: only an attorney reviewing your records can confirm the real deadline.
Use the state where the patient lived when the complication was diagnosed.
An estimate is fine. This year matters because some states also apply a repose period. Those periods usually run from the date the device was first sold rather than the date it was implanted, so the implant year is only a rough stand-in.
Catheter fracture, migration, bloodstream infection, blood clot, or another injury linked to the port.
Wrongful death claims follow a separate deadline in every state.
Wrongful death periods run from the date of death, not the date of diagnosis, so this year drives the estimate.
This checker provides general information only. It is not legal advice, it is not a case evaluation, and using it does not create an attorney-client relationship with Reich & Binstock. Filing deadlines are strict, they vary by state and by claim type, and a missed deadline can end a claim permanently. If you would rather write than call, use our contact page. Reich & Binstock, 4265 San Felipe, #1000, Houston, TX 77027.
Filing Bard PowerPort Catheter Lawsuit Nationwide From Texas
Reich & Binstock handles Bard PowerPort lawsuits from patients nationwide. MDL 3081 is handled through the federal court system centralized in Arizona’s District Court. Bard PowerPort lawsuits filed across the country may all be centralized in this multidistrict litigation (MDL).
Being treated or living in Texas isn’t required to file this product liability lawsuit.
Bard PowerPort Lawsuit Claims in Houston and Harris County
Houston matters to the Bard PowerPort lawsuits filed, which have nothing to do with jurisdiction. The Texas Medical Center is the world’s largest medical complex, and implanted ports are a chemotherapy device. MD Anderson Cancer Center, Houston Methodist Hospital, Memorial Hermann-Texas Medical Center, and Baylor St. Luke’s Medical Center place and manage Bard PowerPort devices in enormous volumes, and patients travel from across the country for cancer and other treatments. The operative reports and port device identification records that a Bard PowerPort lawsuit depends on are frequently held by institutions within our law firm’s service area.
Working with our Houston personal injury attorneys means record requests are from a law firm that sends them routinely.
Bard Port Catheter Claims in Fort Bend, Montgomery, Galveston, and Brazoria Counties
Patients in Sugar Land, The Woodlands, Conroe, Katy, Galveston, and Pearland are typically implanted at regional hospitals and then referred to the Medical Center when a severe complication develops. That split raises an early question: whether the injury traces to the device or to how the port was placed and maintained, which can raise a separate medical malpractice question. The answer determines whether a claim belongs in MDL 3081, in a Texas state court malpractice action, or in both.
What to Look For in the Best Lawyers for a Bard PowerPort Lawsuit
When you’re looking for a Bard PowerPort lawyer, ask about practice structure, not adjectives. Ask whether the law firm handles multidistrict litigation (MDL) cases directly or refers them out. Ask about the law firm’s experience with securing expert testimony and identifying defective medical devices because this is the step where weak personal injury cases fall apart.
Ask whether the law firm tries cases in multidistrict litigation (MDL) or if they solely rely on settlement negotiations. Defendants price Bard PowerPort lawsuits and similar claims differently depending on who is representing the plaintiff.
Ask about the legal process and fee structure and how patients are updated during mass tort litigation, since pending MDL dockets and trial schedules are generally measured in years.
Reich & Binstock’s Bard PowerPort litigation team is led by Dennis C. Reich, lead counsel in the Deepwater Horizon litigation and board certified in personal injury trial law, and Robert J. Binstock, board certified by the Texas Board of Legal Specialization. Prospective clients can read what clients say about working with the firm.
We’re currently investigating cases for the current litigation but have a longstanding reputation for securing maximum compensation on behalf of patients throughout the country.
Bard PowerPort Lawsuit FAQs
Is there a Bard PowerPort class action lawsuit?
No. Bard PowerPort lawsuits are filed by individual plaintiffs and coordinated in multidistrict litigation (MDL). Each plaintiff keeps their individual claim, individual settlements, and their own right to a trial.
Bard PowerPort MDL groups are for pretrial efficiency only. Class actions bind all class members to one global settlement. The Bard PowerPort catheter MDL doesn’t exist, which is why there are 3,734 separate Bard PowerPort lawsuits rather than one PowerPort case with 3,734 members.
Call 713-622-7271 for a free case evaluation.
Is there a Bard PowerPort lawsuit settlement yet?
No, there isn’t a Bard PowerPort lawsuit settlement matrix or court-approved compensation tier for the multidistrict litigation (MDL). Bellwether trials run through February 2027.
Settlement negotiations in defective medical device MDL processes usually follow the bellwether process. The first bellwether trial ended without a clean jury verdict on design defect.
Request a free case review to have a Bard PowerPort lawsuit claim evaluated on its own facts.
How much does it cost to file a Bard PowerPort lawsuit?
Nothing upfront. Bard PowerPort lawsuit claims are handled on a contingency fee basis. This means patients don’t pay anything unless they receive a global or individual settlement.
Our Bard PowerPort lawyers cover the cost of records retrieval, expert testimony, and filing lawsuits.
Call 713-622-7271 to schedule a free case review.
Is the Bard PowerPort recalled?
No, the Bard PowerPort device hasn’t been recalled due to serious complications linked to barium sulfate catheter degradation, and the defective device remains on the market.
However, FDA recalls aren’t required for product liability lawsuits. Pending MDL dockets are proceeding on design defect and failure-to-warn theories without one, and there are thousands of pending lawsuits against Bard Access Systems, Inc.
If you still have the Bard PowerPort implanted under the skin, raise concerns with your healthcare provider first.
What if I do not know the brand of my port?
If you suffered injuries from a defective PowerPort, our law firm can evaluate your Bard PowerPort lawsuit claim using hospital records, even if you have no idea what was implanted.
Hospitals must log the manufacturer, catalog number, and lot number of every implanted device. Our experienced attorneys can use the following to identify the implantable device:
Implant operative report naming the manufacturer and device
Product sticker, catalog number, or lot number filed in the chart
Post-implant imaging showing the device configuration
Provide the hospital name and the approximate year the medical device was implanted under the skin, and our law firm will handle the rest.
Can I still file a Bard PowerPort lawsuit if the device was removed years ago?
Often yes. The discovery rule typically tolls the PowerPort device claims from the date the patient’s injury was discovered, not from the date the Bard PowerPort device was implanted. Fractured catheter surface and device fracture migration claims involving the PowerPort catheter are often discovered years after the port removal.
Our Bard PowerPort lawyers can review your personal injury case to determine if you can file a lawsuit.
Can I file a Bard PowerPort lawsuit if the patient has already died?
Yes. If a loved one died as a result of a medical complication linked to a Bard port catheter device, qualifying family members can pursue a survival action and wrongful death claim against Bard Access Systems, Inc.
Call 713-622-7271 to determine if your loved one’s wrongful death claim qualifies for the Bard PowerPort MDL.
How long does a Bard PowerPort lawsuit take?
The Bard Port catheter MDL judge hasn’t announced any timeline. The PowerPort bellwether trials are scheduled through February 2027, with no global settlement program in place yet. For defective medical devices, federal MDL statistics report that these cases run for several years. Coordinated discovery moves on the schedules of various federal court systems, not on the schedules of individual plaintiffs. However, filing a lawsuit early preserves the potential claim for when Bard PowerPort lawsuit settlement negotiations do begin.
Start a free case review to get a realistic assessment of your timeline.
What is the Bard PowerPort made of and why does that matter?
The Bard PowerPort catheter’s tubing is made of ChronoFlex, a polyurethane compounded with barium sulfate, so the tube is visible on X-ray. Barium sulfate is at the center of the litigation.
In several Bard PowerPort lawsuits, plaintiffs allege that particles separate from the medical device and enter the bloodstream. High concentrations or uneven distribution of barium sulfate can weaken catheter walls. The pitted surface irregularities lead to a fractured catheter surface that is a breeding ground for bacterial colonization. The single alleged defect accounts for the claims of a fractured PowerPort catheter, infection, and thrombosis.
If you’ve suffered injuries from a fractured catheter surface, an attorney can help determine if you have a valid Bard PowerPort device fracture claim.
Contact a Bard Port Catheter Lawsuit Attorney For a Free Case Review
If your Bard PowerPort device fractured, migrated, became infected, or caused a blood clot, and it had to be surgically removed or repaired, the Bard PowerPort lawsuit claim is worth reviewing quickly. Our experienced attorneys are reviewing these legal matters at no cost. We’re investigating cases for patients across the country and represent plaintiffs on a contingency-fee basis, so you don’t pay unless we win. Call 713-622-7271 or request a free case review online from our Bard PowerPort lawyers today.There is never a fee unless we recover on your behalf.
Additionally, clients are not obligated to pay expenses if a recovery is not made.